Cellon debuts sterile single-use containers
The range is ideal for use in the handling and storage of biologicals
Called PharmaTainer, the line of products are a range of low particulate, single use bottles and carboys for the storage/transport of bulk vaccines, biopharmaceuticals, culture media and other biotech materials.
The plastic containers are injection blow moulded in an ISO Class 5 (Class100) environment and radiation sterilised. These rigid ultra-clean containers are available in sizes from 125ml to 20L. They are manufactured from resins approved for medical applications in PET or polycarbonate with HDPE closures.
PharmaTainer packaging features three inner layers of poly wrapping to facilitate delivery into cleanroom areas. The inner most layer is vacuum-sealed providing tamper evidence and assurance of an intact sterility barrier.
The range of products feature traceability down to the individual container. Each bottle/carboy is printed with a unique serial number, batch number, expiration date and a machine-readable data matrix. The machine-readable serial number can be readily integrated with the user’s inventory management system.
All PharmaTainer products are produced in a new, moulding facility, dedicated solely to production of sterile, single-use products for biotechnology industries.
European customers may get further information at www.cellon.lu or by email sales@cellon.lu. The products are distributed by Biofluid Focus in North American (www.biofluidfocus.com).
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing
ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity
The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Pharmaceutical
CelLBxHealth and AstraZeneca sign Master Services Agreement
The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform